Stomach (Gastric) Cancer: Our Clinical Trials

Clinical trials are research studies that evaluate the safety and effectiveness of new treatment approaches for a disease. If you are being treated for stomach cancer at Memorial Sloan Kettering, you may be offered the opportunity to take part in a clinical trial at some point during your treatment.

In some cases, a study may give you access to new therapies that are not yet readily available. Clinical trials may also be used to compare diagnostic tests, prevention strategies, or other aspects of your care.

Our clinical trials reflect the collaborative expertise of Memorial Sloan Kettering researchers and clinicians with specialties in gastrointestinal oncology, pathology, genomics, and more. We are examining the effectiveness of immunotherapy drugs, combinations of conventional chemotherapy medicines, and novel targeted therapies, among other areas. We are also investigating novel biomarkers that can help us identify new treatments for stomach cancer, as well as causes of resistance to promising targeted therapies.

We maintain a continually updated listing of stomach cancer clinical trials at Memorial Sloan Kettering that are currently enrolling new patients. To learn more about a study, choose from the list below:

Showing 17 trials
Titlesort icon Investigator
A Phase I Study of ADI-PEG 20 plus FOLFOX in Patients with Advanced Digestive Cancers
[Protocol 14-153]
Harding, James, MD
A Phase I Study of Debio1347 in Patients with Advanced Cancers Containing FGFR Alterations
[Protocol 13-131]
Voss, Martin, MD
A Phase I Study of DLYE5953A in Patients with Advanced or Persistent Solid Tumors
[Protocol 14-089]
Modi, Shanu, MD
A Phase I Study of TAS-102 plus CPT-11 (Irinotecan) in Patients with Advanced Digestive Cancers
[Protocol 13-105]
Saltz, Leonard, MD
A Phase I/II Study of Nivolumab Alone and with Ipilimumab in Patients with Advanced or Metastatic Solid Tumors
Relapsed/Refractory
[Protocol 13-187]
Callahan, Margaret, MD, PhD
A Phase II Study of Afatinib (BIBW 2992) in Patients with Advanced HER2-Positive Esophagogastric Cancer Refractory to Trastuzumab
[Protocol 11-166]
Janjigian, Yelena, MD
A Phase II Study of AMG 337 in Patients with Stomach and Esophageal Cancers with High Levels of the MET Protein
[Protocol 13-261]
Ku, Geoffrey, MD
A Phase II Study of FOLFOX plus Regorafenib in Patients with Inoperable or Metastatic Esophageal and/or Stomach Cancer
[Protocol 13-080]
Janjigian, Yelena, MD
A Phase II Study of Neratinib in Patients with Solid Tumors Containing Mutated HER2
[Protocol 13-140]
Hyman, David, MD
A Phase II Study of Nintedanib in Patients with Advanced Esophagogastric Cancer
[Protocol 14-094]
Janjigian, Yelena, MD
A Phase II Study of SNX-5422 in Patients with Select Advanced HER2 Cancers
[Protocol 13-112]
Voss, Martin, MD
A Phase II Study of the MatriStem Surgical Matrix to Reinforce the Esophagus in Patients Having Surgery for Gastric and Esophageal Cancer
Newly Diagnosed & Relapsed/Refractory
[Protocol 13-178]
Strong, Vivian, MD
A Phase III Study of Standard Chemotherapy with and without Rilotumumab as Initial Treatment in Patients with Metastatic or Inoperable Gastric/Esophageal Cancer
[Protocol 13-091]
Ilson, David, MD
A Pilot Trial of PET Imaging with (89)Zr-DFO-Trastuzumab in Esophagogastric Cancer
[Protocol 13-165]
Carrasquillo, Jorge, MD
A Randomized Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) Treatment versus Conventional DCF with Growth Factor Support in Patients with Unresectable or Metastatic Gastric and Gastroesophageal Junction Cancer
[Protocol 06-103]
Janjigian, Yelena, MD
Coping with Cancer II
[Protocol 14-048]
Epstein, Andrew, MD
Early Onset and Familial Gastric Cancer Registry
[Protocol 05-118]
Kelsen, David, MD